Profil
Kaye Spratt worked as the Director of Preclinical & Quality Control at Sangamo Therapeutics, Inc. from 1997 to 2015.
She also worked as a Senior Scientist at Somatix Therapy Corp.
and as the Vice President of Regulatory & Quality Assurance at Abeona Therapeutics, Inc. Dr. Spratt received her undergraduate degree from Langston University and her doctorate degree from Meharry Medical College.
Ehemalige bekannte Positionen von Kaye Spratt
| Unternehmen | Position | Ende |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2015 |
Somatix Therapy Corp.
 Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Corporate Officer/Principal | - |
| ABEONA THERAPEUTICS INC. | General Counsel | - |
Ausbildung von Kaye Spratt
| Meharry Medical College | Doctorate Degree |
| Langston University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ABEONA THERAPEUTICS INC. | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Somatix Therapy Corp.
Somatix Therapy Corp. BiotechnologyHealth Technology Somatix Therapy Corp. researches, develops, and commercialize proprietary processes for the genetic modification of cells and their use in the treatment of human disease. Somatix's assets include its highly efficient gene transfer technology, broad-based intellectual property, and focused product development programs. The company's most advanced clinical development program, the GVAX cancer vaccine, is in Phase I/II clinical trials for the treatment of metastatic renal cell carcinoma, advanced melanoma, and prostate cancer. It is located in Alameda, CA | Health Technology |
